• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Biotech Strategy 2012 - Licensing, Collaboration, and M&A Trends - Product Image

Biotech Strategy 2012 - Licensing, Collaboration, and M&A Trends

  • Published: November 2012
  • 75 pages
  • GlobalData

Biotech Strategy 2012 - Licensing, Collaboration, and M&A Trends

Summary

Our Biotech Strategy 2012 - Licensing, Collaboration, and M&A Trends report analyzes 20 strategic deals struck by leading and promising biotech companies. The terms and strategic drivers of these deals are analyzed based on acquisition costs, strategic fit, potential revenues, competitive advantage as well as other measures to illustrate the strategies different companies are currently using to gain market share, increase shareholder value and bring innovative and life-saving products to the booming global pharmaceuticals market. This report is an essential source of information and analysis on global strategic deals involving the top players in the global pharmaceuticals market.

Scope

- The report provides full details of 20 significant deals from Q3 2011 to Q3 2012 involving promising biotech companies including deal terms and payment structure. The report provides analysis of the key drivers, trends, and strategies behind deals undertaken by biotech companies across important geographic regions including the US, EU, Asia-Pacific, Brazil, Russia, India, China, and other emerging READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.1.1 Key Questions Answered
2.1.2 Key Benefits
2.2 Upcoming Related Reports
2.3 Recently published reports:
3 Historical Dealmaking Trends
3.1 Overview
3.2 Leading Deal Drivers
3.2.1 The Patent Cliff
3.2.2 Lack of R&D Innovation
3.2.3 Strategic Shift to Emerging Markets
3.3 Overall Deals in Review
3.3.1 Review by Deal Type
3.3.2 Review by Therapy Area
3.4 Biotech Deals in Review
4 Mergers and Acquisitions
4.1 Overview
4.2 Gilead Completes $11.1 Billion Acquisition of Pharmasset
4.2.1 Deal Description
4.2.2 Deal Analysis
4.3 GSK Acquires HGS in $3.6 Billion Deal
4.3.1 Deal Description
4.3.2 Deal Analysis
4.4 Valeant Pharmaceuticals Agrees $2.6 Billion Cash Deal for Medicis Acquisition
4.4.1 Deal Description
4.4.2 Deal Analysis
4.5 Amgen Acquires Micromet in $1.1 Billion Deal
4.5.1 Deal Description
4.5.2 Deal Analysis
4.6 Alexion Completes Acquisition of Enobia Pharma in $1.1 Billion Deal
4.6.1 Deal Description
4.6.2 Deal Analysis
4.7 Alkermes Acquires EDT from Elan in $1 Billion Deal
4.7.1 Deal Description
4.7.2 Deal Analysis
4.8 Celgene Acquires Avila Therapeutics in $947.0m Deal
4.8.1 Deal Description
4.8.2 Deal Analysis
4.9 Jazz Pharmaceuticals Completes $678.4m Acquisition of EUSA Pharma
4.9.1 Deal Description
4.9.2 Deal Analysis
4.10 Jazz Pharmaceuticals Completes $576.5m Merger with Azur Pharma
4.10.1 Deal Description
4.10.2 Deal Analysis
4.11 Biogen Idec Closes $562.5m Deal for the Acquisition of Stromedix
4.11.1 Deal Description
4.11.2 Deal Analysis
5 Licensing Deals
5.1 Overview
5.2 Acorda Signs Marketing License Agreement with Watson Pharma
5.2.1 Deal Description
5.2.2 Deal Analysis
5.3 Baxter Enters Potential $565.0m Deal with Onconova Therapeutics
5.3.1 Deal Description
5.3.2 Deal Analysis
5.4 Exelixis and Merck Involved in “PI3K-d” Licensing Deal
5.4.1 Deal Description
5.4.2 Deal Analysis
5.5 Momenta Enters into Follow-On Biologics Licensing Agreement with Baxter
5.5.1 Deal Description
5.5.2 Deal Analysis
5.6 Nektar and Roche Involved in Manufacturing License Deal
5.6.1 Deal Description
5.6.2 Deal Analysis
6 Collaborations/Partnerships
6.1 Overview
6.2 Ablynx Extends Nanobody Deal with Boehringer Ingelheim
6.2.1 Deal Description
6.2.2 Deal Analysis
6.3 Novartis Pens Partnership with the University of Pennsylvania
6.3.1 Deal Description
6.3.2 Deal Analysis
6.4 Ironwood Enters into Collaboration Agreement with Bionomics
6.4.1 Deal Description
6.4.2 Deal Analysis
6.5 J&J’s Janssen Biotech Unit Inks Collaboration Deal with Genmab
6.5.1 Deal Description
6.5.2 Deal Analysis
6.6 Pfizer and Mylan Pharmaceuticals Enter into Generics Manufacturing Partnership
6.6.1 Deal Description
6.6.2 Deal Analysis
7 Future Outlook
7.1 Overview
7.2 Dealmaking Trends
7.2.1 Biotech companies, like Big Pharma, will pursue deals to increase their global presence
7.2.2 “Small Biotech” will continue to engage in M&A in attempts to make the leap to “Big Biotech”
7.2.3 Biotech deal-making will remain a source of IP for Big Pharma
8 Appendix
8.1 Bibliography
8.2 Abbreviations
8.3 Research Methodology
8.3.1 Coverage
8.3.2 Secondary Research
8.3.3 Expert Panel Validation
8.4 About the Authors
8.4.1 Analyst
8.4.2 Global Head of Healthcare Research and Consulting
8.5 About the Industry Dynamics Team
8.6 GlobalData
8.7 Contact Us
8.8 Disclosure Information
8.9 Disclaimer

1.1 List of Tables
Table 1: Recent and Upcoming US Patent Expirations
Table 2: M&A Deals, 3Q11-3Q12
Table 3: Gilead’s Acquisition of Pharmasset
Table 4: GSK’s Acquisition of HGS
Table 5: Valeant Pharmaceutical’s Acquisition of Medicis
Table 6: Amgen’s Acquisition of Micromet
Table 7: Alexion’s Acquisition of Enobia Pharma
Table 8: Alkermes’ Acquisition of EDT from Elan
Table 9: Celgene’s Acquisition of Avila Therapeutics
Table 10: Jazz Pharmaceuticals’ Acquisition of EUSA Pharma
Table 11: Jazz Pharmaceuticals’ Merger with Azur Pharma
Table 12: Biogen’s Acquisition of Stromedix
Table 13: Acorda’s Licensing Agreement with Watson Pharma
Table 14: Acorda’s Licensing Agreement with Watson Pharma
Table 15: Exelixis’ Licensing Agreement with Merck
Table 16: Momenta’s Licensing Agreement with Baxter
Table 17: Nektar’s Licensing Agreement with Roche
Table 18: Ablynx’s Collaboration with BI
Table 19: Novartis’ Collaboration with the University of Pennsylvania
Table 20: Ironwood’s Collaboration with Bionomics
Table 21: Janssen’s Collaboration with Genmab
Table 22: Pfizer’s Collaboration with the Mylan Pharmaceuticals

1.2 List of Figures
Figure 1: FDA Approvals of NDAs and BLAs, FY2005-FY2011
Figure 2: Deal Analysis - Total Number of Deals and Deal Values ($m), 3Q07-2Q12
Figure 3: Deal Analysis - Deals Distribution, 3Q07-2Q12
Figure 4: Top 10 Therapeutic Areas by number and Value of Deals, 3Q11-2Q12
Figure 5: Biotech Deals Breakdown by Type, Q3 2011-Q3 2012
Figure 6: M&A Spending, Q3 2011-Q3 2012 ($m)
Figure 7: Xyrem Sales as Percentage of Jazz Pharmaceuticals’ Annual Revenues, 2005-2011 ($m)
Figure 8: Licensing Deals1, Q3 2011-Q3 2012
Figure 9: Breakdown of Collaboration deals, Q3 2011-Q3 2012 ($m)
Figure 10: Pfizer:Emerging Markets Revenues as a Percentage of Annual Revenues, 2006-2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos